Mission Therapeutics Strengthens Clinical Development Team with Appointment of Dr Judit Molnar as Senior Director, Translational Medicine

CAMBRIDGE, UK – 4 September 2018 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat mitochondrial diseases, fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Judit Molnar, MD, PhD to Senior Director of Translational Medicine with immediate effect.

Judit has over ten years of experience in translational science and early drug development of which nine years were spent working in the pharmaceutical industry. She has led small molecule drug development programmes across a variety of therapeutic areas including inflammation and fibrotic disorders, which have resulted in lead candidates being progressed from the preclinical stage into the clinic up to Phase II.

Commenting on the appointment, Dr Paul Thompson, Vice President, Clinical Development at Mission said:

“We are pleased to welcome Judit to Mission’s clinical leadership team. Judit’s in-depth clinical knowledge and proven drug development track record will further strengthen our team as we work to translate scientific advances in the DUB field into transformative therapeutics for mitochondrial diseases and fibrosis.

“She joins Mission at an opportune moment as we have just selected a lead candidate inhibitor for our USP30 programme in mitochondrial diseases and fibrosis. Her expertise and insights will prove invaluable as we progress this programme towards clinical studies during 2019.”

Dr Judit Molnar, newly appointed Senior Director, Translational Medicine, Mission Therapeutics, said:

“Mission’s unique science, chemistry and DUB platform, applicable across numerous therapeutic areas with high unmet need, is highly impressive. I am looking forward to working alongside the experienced and dedicated leadership team to advance its ambitious USP30 and other programmes through preclinical and into clinical development.”

Judit joins Mission from GlaxoSmithKline where she was Preclinical Biology Lead in Epigenetics in immuno-inflammation before being promoted to Director of Translational Medicine in 2016. Prior to this she worked from 2008 at Pfizer as a Drug Discovery Scientist and Daphne Jackson Research Fellow. Previously, she was a Research Fellow at Mount Sinai School of Medicine, New York, USA. Judit obtained a PhD in Physiology from Cornell University, New York, USA and completed her medical degree at the Semmelweis University, Budapest, Hungary.

 

FOR MORE INFORMATION:

Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel: +44 (0) 1223 607340

Instinctif Partners

Melanie Toyne-Sewell / Eileen Paul / Priya Kalia

Tel: +44 (0) 20 7457 2020

missiontherapeutics@instinctif.com

 

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases, fibrosis and inflammation. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations (now part of IP Group) and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

Mission Therapeutics Appoints Dr Bobby Soni to its Board of Directors

CAMBRIDGE, UK – 8 March 2018 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Bobby Soni to its Board of Directors with immediate effect. Bobby replaces Rob Woodman as the representative for IP Group plc.

Bobby is currently Director of Healthcare Investments at Touchstone Innovations, now part of the IP Group plc. He joined Touchstone Innovations (previously Imperial Innovations) in 2015 from Novo Seeds, the early stage investment arm of Novo AS where he worked as Investment Director. Bobby has 17 years’ experience in the Life Science industry covering drug development, business development and venture capital investment. He is a Non-Executive Director of Storm Therapeutics, Enterprise Therapeutics, Artios Pharma, Pulmocide, and Autifony.

Bobby has a PhD in Biology from the University of Virginia and an undergraduate degree in Biochemistry from the University of Rochester.

Commenting on the appointment, Dr Anker Lundemose, Mission’s CEO, said:

“On behalf of the Board I am pleased to welcome Bobby to the Board of Mission Therapeutics. His strong life sciences background and range of experiences within the pharmaceutical and biotechnology sectors will be invaluable as Mission builds its pipeline of first-in-class therapeutic assets across multiple serious disease areas. I would also like to thank Rob for his valuable contribution to Mission and wish him every success in the future.”

 

FOR MORE INFORMATION:

Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel: +44 (0) 1223 497199

Instinctif Partners

Melanie Toyne-Sewell / Eileen Paul / Priya Kalia

Tel: +44 (0) 20 7457 2020

missiontherapeutics@instinctif.com

 

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases, fibrosis and inflammation. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations (now part of IP Group) and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

Mission Therapeutics Strengthens Senior Management Team with Appointment of Dr Paul Thompson, Vice President, Clinical Development

CAMBRIDGE, UK – 1 March 2018 – Today Mission Therapeutics, a drug discovery and development company focused on treating fibrosis, neurodegenerative and other diseases by selectively targeting deubiquitylating enzymes (DUBs), announced the promotion of Dr Paul Thompson to Vice President, Clinical Development with immediate effect.

Dr Thompson has over 15 years’ experience in translational research and early clinical development. He joined Mission as Medical Director for CNS in 2016 from ONO Pharma UK, where he was Clinical Science Director. Prior to this he worked at GlaxoSmithKline, where he led global project teams as Director of Discovery Medicine in Neurology, following previous roles in laboratory biomarker research and experimental medicine study leadership. Dr Thompson holds an MBiochem from the University of Oxford and a PhD in Immuno- and Cell Biology from UCL.

He is also a member of the British Pharmacological Society, Society for Neuroscience and American Academy of Neurology, and is currently the Principal Investigator on a Target Validation award from the Michael J Fox Foundation.

Commenting on the appointment, Dr Anker Lundemose, Mission’s CEO, said:

“Paul’s promotion reinforces our drug discovery and development expertise as we continue our mission to translate scientific advances in the DUB field into transformative therapies. He has already made a substantial contribution to the development of our internal pipeline. He will continue to play a pivotal role in driving the pre-clinical validation and prioritisation of our first-in-class compounds as we progress them towards clinical testing.”

Dr Paul Thompson, newly appointed VP, Clinical Development, Mission Therapeutics, said:

“This is an exciting opportunity to further influence and shape the Company’s therapeutic programs at the senior management level. I look forward to working with the team to continue improving our understanding of DUBs as therapeutic targets and their multiple potential applications to serious diseases with high unmet need, including fibrosis, rare mitochondrial disease and neurodegeneration.”

 

FOR MORE INFORMATION:

 Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel: +44 (0) 1223 497199

 Instinctif Partners

Melanie Toyne-Sewell / Eileen Paul / Priya Kalia

Tel: +44 (0) 20 7457 2020

missiontherapeutics@instinctif.com

 

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases, fibrosis and inflammation. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations (now part of IP Group) and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

Mission Therapeutics’ Highlights Positive Parkinson’s Disease USP30 Target and Inhibitor Data at the Society for Neuroscience 2017 Annual Meeting

CAMBRIDGE, UK –15 November 2017 – Mission Therapeutics, the leading drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, fibrosis, and other diseases with high unmet medical need, is presenting two posters with new research and preclinical data from its USP30 inhibitor Parkinson’s disease programmes today at Neuroscience 2017, the 47th Annual Meeting of the Society for Neuroscience, in Washington, DC. The meeting is the world’s largest neuroscience conference.

USP30 is a mitochondrial-associated DUB that has emerged as a promising new target in Parkinson’s disease. It has been implicated in the control of mitophagy, a cellular mitochondrial quality control mechanism. This process regulates the selective clearance of poorly functioning mitochondria by modifying levels of a protein called ubiquitin.

Failure of mitochondrial quality control results in the accumulation of dysfunctional energy-producing mitochondria, which causes oxidative stress. This stress eventually leads to a pathological mechanism that can result in Parkinson’s disease, and involves the degeneration of the highly-active substantia nigra neurons in the brain. Mission Therapeutics is developing potent and selective inhibitors against USP30 which can help improve mitochondrial quality control, with the aim of halting or slowing down the development of Parkinson’s.

Dr Anker Lundemose, Chief Executive Officer of Mission Therapeutics, said:

“DUBs are playing an emerging role as targets across a number of serious diseases, as highlighted in our team’s recently-published Nature Reviews Drug Discovery paper. The data from the studies presented at this conference further enhances our understanding of the cellular mechanisms of USP30 and the significance of inhibiting this particular DUB in Parkinson’s disease. Our research is also providing invaluable information that is helping to shape our preclinical development strategy.”

Details of Poster Presentations:

Poster# 759.03/Title: USP30 inhibitors for Parkinson’s Disease

Poster# 759.04/Title: Targeting USP30 in Parkinson’s iPSC-derived dopamine neurons

Session Title: The Pathogenesis Mechanisms of Mitochondria in Parkinson’s Disease

Session Number: 759

Session Time: Wednesday November 15th, 2017 1.00 pm – 5:00 pm ET

The meeting will be attended by two scientists from Mission Therapeutics’ CNS team: Dr Paul Thompson, Medical Director, CNS Translational Medicine and Dr Marc Watson. Principal Scientist, CNS.

 

FOR MORE INFORMATION:

Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel: +44 (0) 1223 497199

Instinctif Partners

Melanie Toyne-Sewell / Eileen Paul / Priya Kalia

Tel: +44 (0) 20 7457 2020

missiontherapeutics@instinctif.com

Westwicke Partners (U.S.)

Chris Brinzey

Tel: +1 339-970-2843

Chris.brinzey@westwicke.com

 

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, fibrosis, inflammation, cancer and other diseases of unmet need. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

 

 

Mission Therapeutics’ Scientists Presenting Novel Parkinson’s USP30 Target and Inhibitor Data at the Society for Neuroscience 2017 Annual Meeting

 

CAMBRIDGE, UK – November 1 2017 – Mission Therapeutics, the leading drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, is presenting research and preclinical data on its USP30 inhibitor Parkinson’s disease programmes as two posters at Neuroscience 2017, the 47th Annual Meeting of the Society for Neuroscience, in Washington, DC. The meeting is the world’s largest neuroscience conference.

Mission Therapeutics’ CNS scientists Dr Paul Thompson, Medical Director, CNS Translational Medicine and Dr Marc Watson. Principal Scientist, CNS will be available to meet during the conference: To arrange a time, email: info@missiontherapeutics.com

Details of Poster Presentations:

Poster #759.03/Title: USP30 inhibitors for Parkinson’s disease

Poster #759.04/Title: Targeting USP30 in Parkinson’s iPSC-derived dopamine neurons

Session Title: The Pathogenesis Mechanisms of Mitochondria in Parkinson’s Disease

Session Number: 759

Session Time: Wednesday November 15th, 2017 1.00 pm – 5:00 pm ET

 

FOR MORE INFORMATION:

Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel: +44 (0) 1223 497199

Instinctif Partners

Melanie Toyne-Sewell / Eileen Paul / Priya Kalia

Tel: +44 (0) 20 7457 2020

missiontherapeutics@instinctif.com

Westwicke Partners (U.S.)

Chris Brinzey

Tel: +1 339-970-2843

Chris.brinzey@westwicke.com

 

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, fibrosis, inflammation, cancer and other diseases of unmet need. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

 

 

Mission Therapeutics Presenting at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference

Preclinical data will be presented on novel USP30 inhibitors being developed as potential therapies for Parkinson’s disease

Program of research supported by grant from The Michael J. Fox Foundation for Parkinson’s Research

CAMBRIDGE, UK – 30 October 2017 – Mission Therapeutics announced that its Medical Director, CNS Translational Medicine, Dr Paul Thompson will be delivering a presentation today at the Parkinson’s Disease Therapeutics Conference in New York City. Mission Therapeutics is the leading drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, cancer, and other diseases with high unmet medical need.

The conference is The Michael J. Fox Foundation for Parkinson’s Research (MJFF)’s 11th annual scientific conference and the only one in the world focused exclusively on Parkinson’s disease drug development.

Mission Therapeutics’ presentation, entitled “Validation of USP30 as a Therapeutic Target for Parkinson’s Disease Modification,” will be given during the “Emerging Targets Advancing Treatments Session,” between 9.00h-10.40h ET.

In his presentation, Dr Thompson will share preclinical data generated by Mission Therapeutics as part of their development of potent and selective USP30 inhibitors, ranging from simple in vitro systems through to translationally relevant stem cell-derived Parkinson’s disease models. He will outline some of the scientific mechanisms as well as the clinical potential of USP30 inhibitors in Parkinson’s disease.

USP30 is a mitochondrial-associated DUB that has been highlighted as a promising new target in Parkinson’s disease. It has been implicated in the control of mitophagy – a process that regulates the selective clearance of poorly functioning mitochondria by modifying levels of a protein called ubiquitin. Failure of mitochondrial quality control may lead to degeneration of the highly active substantia nigra neurons in the brain, a pathological mechanism that can result in Parkinson’s disease.

Dr Anker Lundemose, Chief Executive Officer of Mission Therapeutics, said:

“Being invited to speak at The Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference, as well as receiving a grant from the organisation, is a great honour. It is also an endorsement of the potential clinical utility of inhibiting USP30 as a treatment for Parkinson’s disease. In the immediate term the data from our studies are promoting our understanding of the scientific mechanisms and consequences of USP30 inhibition in Parkinson’s disease. They also inform our active USP30 inhibitor preclinical development strategy.”

Mission Therapeutics and the University of Oxford were awarded a grant from MJFF in April 2017.

 

FOR MORE INFORMATION:

Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0)1223 607 360

Instinctif Partners
Melanie Toyne-Sewell / Eileen Paul / Priya Kalia
Tel: +44 (0) 20 7457 2020
missiontherapeutics@instinctif.com

Westwicke Partners (U.S.)
Chris Brinzey
Tel: +1 339-970-2843
Chris.brinzey@westwicke.com

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, fibrosis, inflammation, cancer and other diseases of unmet need. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

Parkinson’s Disease
Parkinson’s disease is a chronic, degenerative neurological disorder that affects one in 100 people over age 60. There is no objective test, or biomarker for Parkinson’s disease, so the rate of misdiagnosis can be relatively high. Estimates of the number of people living with the disease therefore vary, but recent research indicates that at least one million people in the United States, and more than five million worldwide, have the disease.

About the Parkinson’s Disease Therapeutics Conference
The Parkinson’s Disease Therapeutics Conference brings together 300 research and business development professionals from both academia and industry and showcases the most exciting and innovative research from The Michael J. Fox Foundation’s research portfolio. Novel advances in basic and translational research from both academic and industry labs are highlighted through speaker presentations and a poster session. The event is a platform for field leaders to share new and unpublished results and for fostering new relationships and collaborations.

Mission Therapeutics’ Scientists Highlight Significance of Deubiquitylating Enzymes (DUBs) as Key Drug Targets

Keynote Nature article reviews drug discovery opportunities in multiple disease areas of unmet need

CAMBRIDGE, UK – 29 September 2017 – An article entitled “Deubiquitylating enzymes (DUBs) and drug discovery: emerging opportunities,” written by the drug discovery team at Mission Therapeutics was published online today in the scientific journal Nature Reviews Drug Discovery.

The peer-reviewed article outlines how understanding the physiological and pathophysiological roles of human DUBs has accelerated over the past decade. It also highlights how elucidating the biological complexities of this enzyme family is providing opportunities for the development of potentially transformative therapies for a range of clinical indications.

The article is authored by Company co-founders and scientists, including Dr Jeanine A. Harrigan and Professor Steve Jackson FRS.

DUBs comprise a group of some 100 proteins that are known to play important roles in regulating ubiquitylation, the process whereby ubiquitin – a small protein so called because it is present in all complex organisms and virtually all cells in the body – controls protein homeostasis, protein activity, intracellular location, and sub-cellular turnover or degradation.

The clinical development of DUB inhibitors initially proved challenging, in large part due to issues linked to specificity and selectivity. However, recent progress in DUB enzymology, biology and technological developments, described in the review, has confirmed that DUBs are druggable, novel therapeutic targets. As a result, first-generation inhibitors are now moving into, or are on the threshold of entering, patient trials in a number of clinical settings.

Professor Steve Jackson, Co-Founder and CSO, Mission Therapeutics, and senior author on the paper, commented: “This article in Nature Reviews Drug Discovery covers seminal advances that have yielded critical insights into DUB target biology and chemistry over the past decade. A strong foundation in DUB research has been fundamental to Mission Therapeutics’ novel target validation and drug discovery platforms. To date, the platform has demonstrated the diverse clinical potential of novel chemistries selectively targeting different members of the DUB enzyme class.”

Dr Anker Lundemose, Chief Executive Officer, Mission Therapeutics, added: “This review showcases Mission’s leadership position and strength in the DUB field. It also re-enforces the value of our proprietary DUB platform for the discovery and development of first-in-class drugs that selectively target specific disease-associated DUBs. We are now progressing several programmes through preclinical development exemplifying our platform’s translational potential.”

 

FOR MORE INFORMATION:

Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel: +44 (0)1223 607 360

 

Instinctif Partners

Melanie Toyne-Sewell / Eileen Paul / Priya Kalia

Tel: +44 (0) 20 7457 2020

missiontherapeutics@instinctif.com

 

Westwicke Partners (U.S.)

Chris Brinzey

Tel: +1 339-970-2843

Chris.brinzey@westwicke.com

  

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, fibrosis, inflammation, cancer and other diseases of unmet need. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

 

Mission Therapeutics Appoints Scientific Advisory Board

Cambridge, UK – 27 June 2017 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat serious diseases including mitochondrial diseases, neurodegeneration, inflammation and cancer, today announced the formation of its inaugural Scientific Advisory Board (SAB).

Mission’s co-founder and CSO, Professor Steve Jackson, FRS, FMedSci will chair the SAB, where he will be joined by four independent, internationally renowned scientists:

  • Professor Sir Philip Cohen, FRS, FRSE, FFMedSci, FAA, Professor of Enzymology and Deputy Director of the Division of Signal Transduction Therapy, School of Life Sciences, University of Dundee, Scotland
  • Professor Patrick Chinnery, FRCP FMedSci, Head of the Department of Clinical Neurosciences, University of Cambridge, England
  • Professor Jacob Corn, Director at the Innovative Genomics Institute, and Assistant Adjunct Professor in the Department of Molecular and Cell Biology, University of California, Berkeley, USA
  • Professor Titia Sixma, Group Leader and Head of Biochemistry Division at the Netherlands Cancer Institute, Professor at Erasmus MC Rotterdam, The Netherlands

Mission has built a leadership position and strength in the DUB field, and the SAB will provide strategic advice to the Company as it shapes and progresses its therapeutic programs and pipeline of first-in-class DUB inhibitors.

On welcoming the members to the SAB, Dr. Anker Lundemose, Mission’s CEO, said:
“We have attracted a prestigious group of experts to our Scientific Advisory Board, where they bring a wealth of experience across, cell signaling, posttranslational modifications, mitochondrial diseases, neurodegeneration and oncology.

“The formation of this Board will help drive forward the clear clinical potential of our unique DUB platform for the production of first-in-class compounds targeting specific disease-associated DUBs for key indications where effective therapies are currently unavailable. The SAB members’ insights and guidance will prove invaluable as we prioritize and advance our programs.”

Biographies

Professor Steve Jackson, FRS, FMedSci
Prof. Jackson’s research and discoveries in protein ubiquitylation and deubiquitylation led to the founding of Mission to explore new therapeutic opportunities across various disease areas. He is Professor of Biology at the University of Cambridge and Head of Cancer Research UK Laboratories at the Gurdon Institute, Cambridge. As a pioneer in the field of DNA repair and DNA-damage signalling, Prof. Jackson’s research has shaped our understanding of cellular responses to DNA damage and of how defects in these responses contribute to disease. Prof Jackson founded KuDOS Pharma that was acquired by AstraZeneca in 2006. Olaparib, which was developed by KuDOS, was approved for advanced BRCA+ ovarian cancer in USA and Europe in 2014.

Professor Sir Philip Cohen, FRS, FRSE, FMedSci
For 45 years, Prof. Cohen has studied protein phosphorylation in cell regulation and human disease, and made various major contributions to the field. He is now working to unravel signaling networks within the innate immune system involving protein ubiquitylation and phosphorylation during bacterial and viral infections. Prof Cohen is also involved in commercial activities based in Dundee and is frequently cited as the magnet for academics and biotechnology companies and economic regeneration, as 15% of the Dundee economy is from biotech and its employees.

Professor Patrick Chinnery, FRCP FMedSci
Prof. Chinnery began research studying links between mitochondrial DNA and human disease, and is interested in mechanisms of mitochondrial inheritance. His research has involved identifying nuclear and mitochondrial gene defects causing mitochondrial disorders, dissecting downstream disease mechanisms and studying molecular and cellular bases of mitochondrial DNA inheritance – most recently through the UK 100,000 Genomes Project. His active clinical translational research studies the natural history of mitochondrial diseases linked to development of new treatments. Prof. Chinnery has an interest in mitochondrial mechanisms in common diseases, particularly neurodegenerative disorders.

Professor Jacob Corn
Over the last fifteen years Prof. Corn has bridged academia and industry, working in therapeutic areas that include infectious disease, neurobiology, and oncology. He has an interdisciplinary approach to determine cellular mechanisms underlying human disease, with a particular interest in genome editing, DNA repair, and ubiquitin signaling. Prof. Corn is interested in new models for collaboration between academia and industry, mentoring at the interface of these two areas, and promoting entrepreneurship. His research aims to “bring about the end of genetic disease through the development and application of next-generation genome editing technologies.” Prof. Corn is dedicated to improving human health through understanding of disease mechanisms.

Professor Titia Sixma
Prof. Sixma’s research group studies ubiquitin conjugation/deconjugation and DNA repair using a combination of structural methods and biochemistry to understand basic cellular processes. Her aim is to understand structural aspects of the errors that occur in cell biology that lead to cancer development. A major aspect of Prof. Sixma’s work uses protein crystallography, biochemical and biophysical techniques to understand the catalytic activities of deubiquitylating enzymes (DUBs) and how they are regulated by protein partners, cofactors and other domains outside the DUB catalytic subunit. She also collaborates with cell biologists to improve understanding of carcinogenesis as well as the molecular mechanisms that could provide a basis for novel and/or improved drug design.

NOTES TO EDITORS:

About Mission Therapeutics
Mission Therapeutics is discovering and developing first-in-class therapeutics that inhibit disease-associated deubiquitylating enzymes (DUBs) involved in serious diseases including mitochondrial diseases, neurodegeneration, inflammation and cancer.

Mission has built a proprietary world-leading DUB platform that is generating a rich pipeline of highly potent and specific small molecule drug candidates. These candidates have excellent clinical and commercial potential. Using patient selection strategies, the Company is now progressing several programs towards clinical development.

The Company has strong collaborations with key academic and research centers including Cancer Research UK Laboratories & Gurdon Institute at University of Cambridge, Oxford Parkinson’s Disease Centre at University of Oxford, and the Wellcome Trust Mitochondrial Research Centre at Newcastle University.

In February 2016, Mission completed an $86m financing that was led by Touchstone Innovations and Woodford Patient Capital Trust, and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One.

Mission Therapeutics was founded in 2011 and its leadership team comprises international, commercial and scientific experience. The Company is based at the Babraham Research Campus, Cambridge, UK.

Find out more about Mission Therapeutics at www.missiontherapeutics.com or follow @MISSIONTherapeu.

About deubiquitylating enzymes (DUBs)
DUBs comprise a group of around 100 proteins that play important roles in regulating ubiquitylation. This process is where ubiquitin – a small regulatory protein so called because it is present in all complex organisms and virtually every all cells in the body – controls protein homeostasis, protein activity, intracellular location, and sub-cellular turnover or degradation.

For more information, contact:

Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0) 1223 497199

Instinctif Partners
Melanie Toyne-Sewell / Eileen Paul / Priya Kalia
Tel: +44 (0) 20 7457 2029 / +44 (0) 20 7457 2061
missiontherapeutics@instinctif.com

Westwicke Partners (U.S.)
Chris Brinzey
Tel: +1 339-970-2843
chris.brinzey@westwicke.com

Mission Therapeutics nominated as Biotech and Money 2017 Awards Double Finalist

Cambridge, UK – 9 June 2017 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative and other diseases, has been announced as a finalist in two categories for the Biotech and Money 2017 Awards.

The Biotech and Money 2017 Awards celebrate funding, finance and investment successes over the past 12 months across the British Life Sciences sector.

Mission has been nominated for UK Growth Life Sciences Company of the Year and UK Life Science Private CEO of the Year.

The first nomination is for Mission’s novel approach to treating a range of clinical indications by targeting human DUBs and overcoming specificity and selectivity barriers, progressing the development of promising therapies. The second nomination is for CEO Anker Lundemose, who has played a pivotal role in in Mission’s transition from discovery to clinical development, leveraging over two and a half decades of biopharma expertise.

At last year’s Awards, Mission won the ‘One to Watch’ Private UK Life Science Company of the Year Award.

Winners of each category are determined on the basis of online voting (which can be done here http://bit.ly/2r8Zne2) and a live voting session during the Awards dinner, which will be held on 14 September in London.

Details of the event are here: Biotech and Money Assembly and Awards Gala Dinner

  

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, inflammation, cancer and other diseases of unmet need. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

About Biotech and Money Awards 2017

Biotech and Money Assembly and Awards is a 250 person Gala Dinner celebrating the UK’s funding, finance and investment successes in the sector over the last 12 months. Leading lights and emerging stars, C-suite executives, impactful investors and powerful KOLs in the sector will be celebrating at one of London’s finest banqueting halls; Merchant Taylors Hall on 14th September 2017, from 6pm-11pm.

For more information, please visit the website: http://www.biotechandmoney.com/gala-dinner

For more information, please contact:

Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel: +44 (0) 1223 497199

Instinctif Partners

Melanie Toyne-Sewell / Eileen Paul / Priya Kalia

Tel: +44 (0) 20 7457 2020

missiontherapeutics@instinctif.com

Westwicke Partners (U.S.)

Chris Brinzey

Tel: +1 339-970-2843

chris.brinzey@westwicke.com

Mission Therapeutics and University of Oxford Awarded Research Grant from the Michael J. Fox Foundation

Collaborative team to progress novel USP30 inhibitors to develop potential therapies for Parkinson’s disease

CAMBRIDGE, UK – 11 April 2017 – On World Parkinson’s day, Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, cancer and other diseases with high unmet medical need, announced that it has been awarded a grant from the Michael J. Fox Foundation for Parkinson’s Research (MJFF).

This research grant will support the testing of Mission Therapeutics’ potent and selective USP30-targeted inhibitors in translationally relevant stem cell-derived Parkinson’s disease models developed by Professor Richard Wade-Martins and his research group at the University of Oxford.

USP30, a mitochondrial associated DUB, has been implicated in the control of mitophagy – a process where dysfunctional mitochondria are selectively cleared from the cell. Failure of mitochondrial quality control may lead to degeneration of the highly active substantia nigra neurons in the brain, a pathological mechanism which results in Parkinson’s disease.

The inhibition of USP30 is being studied by Mission Therapeutics to see if this promotes mitophagy and thus improves cellular resilience in this and other neurodegenerative diseases. The objective of the research collaboration with Professor Richard Wade-Martins is to test Mission’s potent and selective USP30 inhibitors in a range of disease models – induced Pluripotent Stem Cells (iPSC)-derived from patients with sporadic and familial Parkinson’s disease.

Shalini Padmanabhan, PhD, Associate Director of Research Programs at MJFF:
“USP30 is one of the more promising DUBs associated with mitophagy, in terms of published data and feasibility of compound development. We hope that this collaboration between Mission Therapeutics and Oxford Parkinson’s Disease Centre will promote our understanding of the mechanisms and consequences of USP30 inhibition in Parkinson’s disease.”

Dr Michael Koslowski, Executive Vice President, Research and Development and Chief Medical Officer of Mission Therapeutics, added:
“Receiving funding from the Michael J. Fox Foundation is a great accolade, recognizing the quality of the research being done by Mission Therapeutics and Prof. Wade-Martins and his group. The collaborative study will provide key data that will guide the clinical development strategy of our USP30 inhibitor programme. We are working hard to find new ways in which to tackle this difficult disease, which is especially highlighted during this World Parkinson Awareness week, for patients and their families.”

Parkinson’s disease is a chronic, degenerative neurological disorder that affects one in 100 people over age 60. There is no objective test, or biomarker, for Parkinson’s disease, so the rate of misdiagnosis can be relatively high. Estimates of the number of people living with the disease therefore vary, but recent research indicates that at least one million people in the United States, and more than five million worldwide, have Parkinson’s disease.

 

FOR MORE INFORMATION:

Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0) 1223 497199

Instinctif Partners
Melanie Toyne-Sewell / Eileen Paul / Priya Kalia
Tel: +44 (0) 20 7457 2020
missiontherapeutics@instinctif.com

Westwicke Partners (U.S.)
Chris Brinzey
Tel: +1 339-970-2843
Chris.brinzey@westwicke.com

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics, an early-stage drug development company targeting the ubiquitin pathway for the treatment of cancer, neurodegenerative, and other diseases of unmet need. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Cancer Research UK Laboratories and the University of Cambridge’s Jackson Laboratories at the Gurdon Institute, and a leadership team that has broad international, commercial and scientific experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

About the Michael J. Fox Foundation for Parkinson’s Research

As the world’s largest nonprofit funder of Parkinson’s research, the Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers.

In addition to funding more than $700 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials